登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC
ClinicalTrials.gov 上登记的一项食管鳞状细胞癌开放试验,由浙江省肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06190639,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 8
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(8 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Histologically confirmed T1-3N+M0 thoracic esophageal squamous cell cancer (AJCC 8th)
入选标准第 4 条
Glucocorticoids are required for 14 days prior to treatment (daily>10 mg equivalent dose of prednisone) or other immunosuppressive drugs for systemic treatment.
排除标准第 8 条
Participants were found to have active hepatitis B (Hepatitis B surface antigen [HBsAg] positive or hepatitis C virus (HCV) positive (HCV RNA positive) Sex). Participants with prior HBV infection or recovered HBV infection (defined as having hepatitis B core antibodies [HBcAb] and no HBsAg) were eligible. HBV DNA must be obtained from these patients before treatment. Participants who are HBV carriers or require antiviral therapy are not eligible to participate. Participants who were positive for HCV antibodies were eligible only if the PCR for HCV RNA was negative.
排除标准第 16 条
ECOG PS 0-1
入选标准第 3 条
WBC ≥2000/μL;
入选标准第 9 条
Neutrophils ≥1500/μL;
入选标准第 10 条
Platelets ≥100 x 103/μL;
入选标准第 11 条
Hemoglobin ≥9.0 g/dL;
入选标准第 12 条
Creatinine: Serum creatinine ≤1.5 x above normal (ULN) or creatinine removal rate > 50mL/ min (Cockcroft/Gault formula);
入选标准第 13 条
AST ≤3 x ULN;
入选标准第 14 条
ALT ≤3 x ULN;
入选标准第 15 条
Total bilirubin ≤1.5 x ULN (except for subjects with Gilbert syndrome, where total bilirubin must be < 3 x ULN);
入选标准第 16 条
All participants must be confirmed disease-free by physical and imaging examinations within 4 weeks prior to enrollment. Imaging examinations must include CT/MRI scans of the neck, chest and abdomen.
入选标准第 7 条
A known history of testing positive for human immunodeficiency virus (HIV) or a known history of acquired immunodeficiency syndrome (AIDS)
排除标准第 9 条
Active malignancy within the last 3 years, other than locally curable cancers that have apparently been cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.
排除标准第 13 条
Women of child bearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity of HCG is 25 IU/L or equivalent) within 24 hours before starting study treatment.
入选标准第 19 条
Women must be non-breastfeeding
入选标准第 20 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06190639,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Signed an Informed Consent Form Participant type and target disease characteristics: ECOG PS 0-1 Histologically confirmed T1-3N+M0 thoracic esophageal squamous cell cancer (AJCC 8th) can tolerate radical resection of esophageal cancer Resection must be performed within 4-12 weeks prior to enrollment All participants must be confirmed disease-free by physical and imaging examinations within 4 weeks prior to enrollment. Imaging examinations must include CT/MRI scans of the neck, chest and abdomen. All baseline laboratory tests will be evaluated as required and results should be available within 28 days prior to enrollment. Laboratory test values must be selected according to the following criteria (CTCAE V5.0): WBC ≥2000/μL; Neutrophils ≥1500/μL; Platelets ≥100 x 103/μL; Hemoglobin ≥9.0 g/dL; Creatinine: Serum creatinine ≤1.5 x above normal (ULN) or creatinine removal rate > 50mL/ min (Cockcroft/Gault formula); AST ≤3 x ULN; ALT ≤3 x ULN; Total bilirubin ≤1.5 x ULN (except for subjects with Gilbert syndrome, where total bilirubin must be < 3 x ULN); Age and fertility status: Age ≥18 years old Women of child bearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity of HCG is 25 IU/L or equivalent) within 24 hours before starting study treatment. Women must be non-breastfeeding排除标准:Exclusion Criteria:
Target disease The presence of locally advanced unresectable (regardless of stage) or metastatic disease. Cervical and abdominal esophageal tumors. Medical history and concurrent diseases Complete resection followed by treatment for the removed esophageal cancer (e.g., chemotherapy, targeted drugs, radiation, or biotherapy). Participants with ≥ grade 2 peripheral neuropathy Participants with active, known, or suspected autoimmune diseases. Participants with type I diabetes, hypothyroidism requiring only hormone replacement therapy, skin conditions that do not require systemic treatment (such as vitiligo, psoriasis, or hair loss), or conditions that are not expected to recur without external irritants, may be enrolled. Glucocorticoids are required for 14 days prior to treatment (daily>10 mg equivalent dose of prednisone) or other immunosuppressive drugs for systemic treatment. A known history of testing positive for human immunodeficiency virus (HIV) or a known history of acquired immunodeficiency syndrome (AIDS) Participants with a serious or uncontrolled medical condition. Radiotherapy, chemotherapy, immunotherapy, esophagectomy, esophagus-gastric junction, and gastric surgery were performed before the trial. Participants with severe cardiovascular or pulmonary disease, interstitial pneumonia, or a history of prior interstitial pneumonia. Active malignancy within the last 3 years, other than locally curable cancers that have apparently been cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast. Participants with a serious or uncontrolled medical condition Physical and laboratory examination Participants were found to have active hepatitis B (Hepatitis B surface antigen [HBsAg] positive or hepatitis C virus (HCV) positive (HCV RNA positive) Sex). Participants with prior HBV infection or recovered HBV infection (defined as having hepatitis B core antibodies [HBcAb] and no HBsAg) were eligible. HBV DNA must be obtained from these patients before treatment. Participants who are HBV carriers or require antiviral therapy are not eligible to participate. Participants who were positive for HCV antibodies were eligible only if the PCR for HCV RNA was negative. Allergies and adverse drug reactions History of allergy or hypersensitivity to study drug ingredients. A history of severe hypersensitivity to any monoclonal antibody. Other exclusion criteria Participants who do not understand or may not comply with the requirements of the trial Participants had an active infection requiring systemic treatment in the 28 days prior to first dosing Some obvious diseases that the researchers believe should be excluded from this study
引自 ClinicalTrials.gov, NCT06190639, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06190639,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。